Eli Lilly and Company (LLY) Key Ratios
$1,149.36
As on 04-Sep-2026 16:27EDT
Market cap
$1,034,063 Mln
Revenue (TTM)
$79,666 Mln
P/E Ratio
38.9
P/B Ratio
30.5
Div. Yield
0.6 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 16.04 | 47.67 | 49.58 | 39.23 | 24.41 |
| EBIT | -- | -- | 39.73 | 47.94 | 27.64 |
| Net Profit | -4.07 | 25.34 | 93.55 | 63.63 | 33.64 |
| EPS | -3.83 | 26.20 | 94.62 | 62.69 | 35.95 |
| Book Value | -- | -- | 88.04 | 38.15 | 38.03 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 30.33 | 27.79 | 31.17 | 40.46 | 29.88 |
| Net Margin
| -- | 22.13 | 33.53 | -- | -- |
| Return on equity
| 78.37 | 75.02 | 88.42 | 101.35 | 84.84 |
| Return on Capital
| 25.75 | 24.83 | -- | 35.32 | 25.26 |
| Return on Assets
| 15.22 | 14.01 | 16.19 | 21.59 | 14.84 |
| Debt to Equity (x)
| -- | -- | 1.41 | 1.60 | 2.37 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
--
|
35.32
|
25.26
|
16.67
|
23.68
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
88.42
Higher than Peers by 69.45
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
88.42
|
101.35
|
84.84
|
48.93
|
63.63
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
16.19
Higher than Peers by 13.33
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
16.19
|
21.59
|
14.84
|
9.23
|
12.71
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
31.17
Higher than Peers by 15.35
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
31.17
|
40.46
|
29.88
|
20.63
|
25.01
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
33.53
Higher than Peers by 25.29
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
33.53
|
31.66
|
23.51
|
15.36
|
22.13
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
49.58
Higher than Peers by 41.53
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
49.58
|
0.45
|
0.32
|
0.20
|
0.01
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
39.73
Higher than Peers by 31.47
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
39.73
|
95.92
|
91.19
|
-1.37
|
9.89
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
93.55
Higher than Peers by 85.82
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
93.55
|
94.88
|
102.08
|
-16.08
|
11.88
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
94.62
Higher than Peers by 84.22
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
94.62
|
0.96
|
1.02
|
-0.12
|
0.12
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
86.67
Higher than Peers by 81.79
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
86.67
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
1.41
Higher than Peers by 0.82
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
1.41
|
1.60
|
2.37
|
2.34
|
1.52
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.21
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
0.21
|
0.06
|
0.36
|
0.64
|
0.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.35
Lower than Peers by 0.30
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
1.35
|
1.58
|
1.15
|
0.94
|
1.05
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
1.00
Lower than Peers by 0.20
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
1.00
|
1.19
|
0.89
|
0.73
|
0.80
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
35.29
Higher than Peers by 30.52
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
35.29
|
33.16
|
17.24
|
14.49
|
21.53
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
29.47
Higher than Peers by 8.19
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
29.47
|
30.92
|
29.47
|
33.22
|
29.99
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.48
Higher than Peers by 0.08
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
0.48
|
0.68
|
0.63
|
0.60
|
0.58
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
--
|
93.67
|
99.79
|
106.47
|
106.77
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
--
|
368.80
|
289.87
|
259.99
|
225.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
--
|
148.80
|
126.42
|
116.80
|
99.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
--
|
313.66
|
263.24
|
249.67
|
233.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
38.90
Higher than Peers by 0.99
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
38.90
|
46.76
|
65.84
|
100.55
|
55.66
|
|
Peer Median
|
37.91
|
--
|
--
|
--
|
--
|
Price / Book Value
30.52
Higher than Peers by 22.83
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
30.52
|
36.37
|
49.13
|
48.92
|
32.64
|
|
Peer Median
|
7.69
|
--
|
--
|
--
|
--
|
Dividend Yield
0.56
No difference
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
0.56
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.56
|
--
|
--
|
--
|
--
|
EV/EBITDA
25.89
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
25.89
|
35.81
|
47.77
|
64.11
|
41.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
1,034,063
Higher than Peers by 1,031,542
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
1,034,063
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|